Mizuho Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Joseph Catanzaro reaffirmed a Buy rating on Tango Therapeutics (TNGX) with a $40 price target, noting the stock closed at $28.56. This aligns with a broader Strong Buy consensus averaging $42.67. Additionally, J.P. Morgan initiated coverage with a Buy rating and a $46 target on July 15.
In a report released on July 17, Joseph Catanzaro from Mizuho Securities maintained a Buy rating on Tango Therapeutics, with a price target of $40.00. The company’s shares closed last Friday at $28.56.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Catanzaro is a 5-star analyst with an average return of 12.6% and a 46.01% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Tango Therapeutics, Erasca, and Revolution Medicines.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tango Therapeutics with a $42.67 average price target, representing a 49.40% upside. In a report released on July 15, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $46.00 price target.